Revvity Cost of Goods Sold 2010-2025 | RVTY
Revvity annual/quarterly cost of goods sold history and growth rate from 2010 to 2025. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- Revvity cost of goods sold for the quarter ending March 31, 2025 was $0.289B, a 1.92% decline year-over-year.
- Revvity cost of goods sold for the twelve months ending March 31, 2025 was $1.212B, a 0.04% decline year-over-year.
- Revvity annual cost of goods sold for 2024 was $1.217B, a 0.54% increase from 2023.
- Revvity annual cost of goods sold for 2023 was $1.211B, a 8.4% decline from 2022.
- Revvity annual cost of goods sold for 2022 was $1.322B, a 5.15% decline from 2021.
| Revvity Annual Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2024 | $1,217 |
| 2023 | $1,211 |
| 2022 | $1,322 |
| 2021 | $1,394 |
| 2020 | $933 |
| 2019 | $1,488 |
| 2018 | $1,437 |
| 2017 | $1,183 |
| 2016 | $1,101 |
| 2015 | $1,141 |
| 2014 | $1,135 |
| 2013 | $1,181 |
| 2012 | $1,144 |
| 2011 | $1,071 |
| 2010 | $943 |
| 2009 | $850 |
| Revvity Quarterly Cost of Goods Sold (Millions of US $) |
|
|---|---|
| 2025-03-31 | $289 |
| 2024-12-31 | $317 |
| 2024-09-30 | $299 |
| 2024-06-30 | $306 |
| 2024-03-31 | $295 |
| 2023-12-31 | $312 |
| 2023-09-30 | $298 |
| 2023-06-30 | $307 |
| 2023-03-31 | $293 |
| 2022-12-31 | $305 |
| 2022-09-30 | $305 |
| 2022-06-30 | $344 |
| 2022-03-31 | $368 |
| 2021-12-31 | $-10 |
| 2021-09-30 | $338 |
| 2021-06-30 | $543 |
| 2021-03-31 | $523 |
| 2020-12-31 | $-212 |
| 2020-09-30 | $437 |
| 2020-06-30 | $364 |
| 2020-03-31 | $344 |
| 2019-12-31 | $407 |
| 2019-09-30 | $365 |
| 2019-06-30 | $375 |
| 2019-03-31 | $341 |
| 2018-12-31 | $380 |
| 2018-09-30 | $342 |
| 2018-06-30 | $363 |
| 2018-03-31 | $352 |
| 2017-12-31 | $334 |
| 2017-09-30 | $285 |
| 2017-06-30 | $289 |
| 2017-03-31 | $274 |
| 2016-12-31 | $290 |
| 2016-09-30 | $266 |
| 2016-06-30 | $283 |
| 2016-03-31 | $263 |
| 2015-12-31 | $229 |
| 2015-09-30 | $309 |
| 2015-06-30 | $311 |
| 2015-03-31 | $292 |
| 2014-12-31 | $233 |
| 2014-09-30 | $299 |
| 2014-06-30 | $308 |
| 2014-03-31 | $295 |
| 2013-12-31 | $313 |
| 2013-09-30 | $289 |
| 2013-06-30 | $299 |
| 2013-03-31 | $280 |
| 2012-12-31 | $303 |
| 2012-09-30 | $279 |
| 2012-06-30 | $283 |
| 2012-03-31 | $279 |
| 2011-12-31 | $300 |
| 2011-09-30 | $254 |
| 2011-06-30 | $270 |
| 2011-03-31 | $247 |
| 2010-12-31 | $259 |
| 2010-09-30 | $233 |
| 2010-06-30 | $232 |
| 2010-03-31 | $218 |
| 2009-12-31 | $144 |
| 2009-09-30 | $208 |
| 2009-06-30 | $250 |
| 2009-03-31 | $247 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.864B | $2.755B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $136.013B | 25.51 |
| Elevance Health (ELV) | United States | $93.532B | 12.07 |
| CVS Health (CVS) | United States | $83.782B | 10.41 |
| Cencora (COR) | United States | $56.393B | 20.47 |
| Natera (NTRA) | United States | $21.021B | 0.00 |
| DiDi Global (DIDIY) | China | $20.473B | 31.07 |
| BioMerieux (BMXMF) | France | $15.263B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.189B | 0.00 |
| CochLear (CHEOY) | Australia | $11.336B | 0.00 |
| Solventum (SOLV) | United States | $11.327B | 10.56 |
| ICON (ICLR) | Ireland | $10.910B | 10.14 |
| Doximity (DOCS) | United States | $10.660B | 55.44 |
| Viatris (VTRS) | United States | $10.056B | 3.20 |
| Medpace Holdings (MEDP) | United States | $8.300B | 22.04 |
| Avantor (AVTR) | United States | $8.164B | 11.86 |
| Sonic Healthcare (SKHHY) | Australia | $8.076B | 0.00 |
| HealthEquity (HQY) | United States | $7.797B | 38.36 |
| Charles River Laboratories (CRL) | United States | $5.668B | 11.18 |
| Amplifon S.p.A (AMFPF) | Italy | $4.736B | 25.00 |
| Bausch + Lomb (BLCO) | Canada | $3.852B | 22.71 |
| BrightSpring Health Services (BTSG) | United States | $3.804B | 35.21 |
| Sotera Health (SHC) | United States | $3.648B | 20.73 |
| Alignment Healthcare (ALHC) | United States | $3.110B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.950B | 33.84 |
| Concentras Parent (CON) | United States | $2.781B | 14.47 |
| Organon (OGN) | United States | $2.373B | 2.52 |
| Premier (PINC) | United States | $2.095B | 14.34 |
| Progyny (PGNY) | United States | $2.001B | 44.08 |
| Ardent Health Partners (ARDT) | United States | $1.857B | 7.93 |
| Agilon Health (AGL) | United States | $1.842B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.776B | 69.53 |
| GoodRx Holdings (GDRX) | United States | $1.634B | 35.50 |
| PACS (PACS) | United States | $1.503B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.243B | 9.46 |
| Teladoc Health (TDOC) | United States | $1.189B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.039B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.952B | 0.00 | |
| CareDx (CDNA) | United States | $0.790B | 12.33 |
| AMN Healthcare Services Inc (AMN) | United States | $0.748B | 5.92 |
| Nutex Health (NUTX) | United States | $0.735B | 14.39 |
| Embecta (EMBC) | United States | $0.710B | 4.86 |
| QDM (QDMI) | Hong Kong, SAR China | $0.671B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.518B | 13.73 |
| Sonida Senior Living (SNDA) | United States | $0.440B | 0.00 |
| Enhabit (EHAB) | United States | $0.407B | 38.29 |
| InnovAge Holding (INNV) | United States | $0.385B | 0.00 |
| LifeMD (LFMD) | United States | $0.341B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.338B | 0.00 |
| SBC Medicals (SBC) | United States | $0.323B | 0.00 |
| DocGo (DCGO) | United States | $0.239B | 9.75 |
| Oncology Institute (TOI) | United States | $0.197B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.177B | 0.00 |
| Beauty Health (SKIN) | United States | $0.132B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.095B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.089B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.087B | 0.00 |
| So-Young (SY) | China | $0.087B | 0.00 |
| OncoCyte (OCX) | United States | $0.083B | 0.00 |
| Biodesix (BDSX) | United States | $0.066B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.059B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| ModivCare (MODV) | United States | $0.020B | 7.10 |
| KindlyMD (KDLY) | United States | $0.018B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |